

Dopamine receptor type 2 (D2R) and ghrelin receptor (GHSR) co-expression alters Ca_{2.2} modulation by G protein signaling cascades.

Santiago Cordisco Gonzalez, Emilio Román Mustafá, Silvia S. Rodriguez, Mario Perello, and Jesica Raingo

ACS Chem. Neurosci., **Just Accepted Manuscript** • DOI: 10.1021/acchemneuro.9b00426 • Publication Date (Web): 06 Dec 2019

Downloaded from pubs.acs.org on December 7, 2019

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Title**Dopamine receptor type 2 (D2R) and ghrelin receptor (GHSR) co-expression alters Ca_v2.2 modulation by G protein signaling cascades.**

Santiago Cordisco Gonzalez¹, Emilio Román Mustafá¹, Silvia S. Rodriguez¹, Mario Perello² and Jesica Raingo^{1*}

¹Laboratory of Electrophysiology and ²Laboratory of Neurophysiology of the Multidisciplinary Institute of Cell Biology (IMBICE), B1904CMA La Plata, Buenos Aires, Argentina.

*Corresponding author jraingo@gmail.com jraingo@imbice.gov.ar

Abstract

Voltage-gated calcium channels type 2.2 (Ca_v2.2) are activated by action potentials at presynaptic terminals, and their calcium current induces neurotransmitter release. In this context, regulating Ca_v2.2 is critical, and one of the most important mechanisms for doing so is through G protein-coupled receptor (GPCR) activity. Two such GPCRs are the ghrelin (GHSR) and the dopamine type 2 (D2R) receptors. We previously demonstrated that constitutive GHSR activity reduces Ca_v2.2 forward trafficking and that ghrelin-induced GHSR activity inhibits Ca_v2.2 currents. On the other hand, dopamine-induced D2R activity also inhibits Ca_v2.2 currents. It has been recently shown that D2R and GHSR form heteromers in hypothalamic neurons. This interaction profoundly changes the signaling cascades activated by dopamine and is necessary for dopamine-dependent anorexia. Here we explored how D2R-GHSR co-expression in HEK293T cells modulates the effect that each GPCR has on Ca_v2.2. We found that D2R-GHSR co-expression reduces the inhibition of Ca_v2.2 currents by agonist-induced D2R activation and added a new source of basal Ca_v2.2 current inhibition to the one produced by GHSR solely expression. We investigated the signaling cascades implicated and found that constitutive GHSR activity, G_q protein and Gβγ subunit play a critical role in these altered effects. Moreover, we found that the effect of D2R agonist on native calcium currents in hypothalamic neurons is reduced when both D2R and GHSR are over-expressed. In summary, our results allow us to propose a novel mechanism for controlling Ca_v2.2 currents involving the co-expression of two physiologically relevant GPCRs.

Keywords

Dopamine, ghrelin, hypothalamus, calcium channels, G protein, heteromers.

Introduction

G protein-coupled receptors (GPCRs) are important for controlling neuronal functions [1-3]. The cellular effects of a given GPCR vary based on neuronal type and environmental conditions. Thus, defining the main G protein subtype that is coupled and the downstream intracellular pathways that are activated is insufficient to explain the diverse functions of a given GPCR. In this context, understanding non-canonical properties of

1 GPCRs, which critically change their global effect, can help to illuminate complex GPCR
2 behavior. Among these non-classical properties are constitutively active states [4-6],
3 promiscuous G protein activation by different natural and pharmacological agonists [7-9],
4 and GPCR homo- and heteromerization [10-12].

5 Several GPCR heteromers have been described with the advance of biochemical
6 and imaging techniques such as FRET (Förster Resonance Energy Transfer) and BRET
7 (bioluminescence resonance energy transfer) [13]. The GPCRs more prone to form
8 heteromers include the dopamine receptors and the ghrelin receptor (GHSR) [14, 15]. A
9 physiologically relevant example of this non-canonical GPCR behavior is the dopamine type
10 2 receptor (D2R) and GHSR heteromerization in hypothalamic neurons, where their
11 interaction is required for the anorexigenic effect of D2R activation by agonists [12]. When
12 both receptors are co-expressed on the same neuron, the dopamine-induced D2R signaling
13 pathway activation switches from adenylate cyclase (AC) inhibition to calcium mobilization
14 from internal stores in a G $\beta\gamma$ - and phospholipase C (PLC)-dependent manner [12, 16]. An
15 important question that arises from these observations is: does D2R-GHSR interaction
16 impact other neuronal targets?

17 D2R and GHSR signaling modulate presynaptic Ca_v2 channels, which are key
18 effectors for their actions. In particular, the activation of these two GPCRs independently
19 inhibits presynaptic Ca_v2.2 subtype, affecting neurotransmitter release [5, 17-19].
20 Dopamine-induced D2R activation reduces Ca_v2.2 currents in a G_{i/o} protein dependent
21 manner, while ghrelin-induced GHSR activation acts through its coupling to G_q protein [5,
22 20]. On the other hand, we have previously demonstrated that constitutive GHSR activity,
23 through the G_{i/o} signaling pathway, affects Ca_v2.2 trafficking to the plasma membrane and
24 consequently reduces Ca_v2.2 calcium currents [21]. Here, we aimed to evaluate if D2R and
25 GHSR co-expression differentially impacts on Ca_v2.2 current modulation.

26 27 **Results and discussion**

28 First we explored the effect of consecutive applications of D2R and GHSR agonists
29 (quinpirole 10 μ M and ghrelin 0.5 μ M) on native Ca_v currents in hypothalamic cultured
30 neurons, where D2R-GHSR co-expression has been previously reported [12]. For both
31 agonists, we observed a range of inhibition on Ca_v currents, as expected for a native system
32 [5, 17]. Specifically, we noticed that neurons with a large inhibitory response to quinpirole
33 exhibited a mild inhibitory response to ghrelin (see example a in figure 1). Conversely,
34 neurons that were less sensitive to quinpirole displayed a large response to ghrelin (see
35 example b in figure 1). Quinpirole and ghrelin effects were reversible upon washout as Ca_v
36 currents were fully recovered (data not shown) were reversible upon washout as Cav
37 currents. We estimated the Spearman's correlation coefficient between the degree of
38 quinpirole- and ghrelin-induced inhibitions and found a significant inverse correlation (figure
39 1). Assuming that larger inhibitory effects are mainly due to higher receptor expression levels
40 and based on the correlation between the effects of ghrelin and quinpirole, we hypothesize
41 that changes in Ca_v current inhibition due to D2R and/or GHSR agonists is a new functional
42 output of D2R-GHSR heteromerization in hypothalamic neurons.





Figure 1. Barium current inhibition by quinpirole and ghrelin are inversely correlated in hypothalamic neurons. Examples of barium current (I_{Ba}) traces before and after consecutive applications of quinpirole (10 μ M, +Quin) and ghrelin (0.5 μ M, +Ghre) from 2 cultured mouse embryonic hypothalamic neurons named a and b. Correlation between the percent inhibition of I_{Ba} by quinpirole versus ghrelin was calculated (Spearman's correlation coefficient, r , and P value indicated). The best lineal fit line is also displayed ($r^2=0.6615$, slope= -0.7633 $P=0.0141$ versus zero).

1

2 We next evaluated this correlation in a more controlled manner by over-expressing
 3 D2R and GHSR in hypothalamic cultured neurons. We used a lentiviral system with a high
 4 efficiency of transduction, resulting in homogeneous expression of each GPCR within the
 5 neuronal population, and evaluated the inhibitory effect of quinpirole and ghrelin in neurons
 6 over-expressing D2R, GHSR, or both GPCRs. Under these experimental conditions, we
 7 expected that over-expressing one receptor, but not the other, would increase the fraction
 8 of over-expressed receptor detached from the other. Conversely, we expected that the
 9 simultaneous over-expression of both receptors would increase the fraction of D2R-GHSR
 10 heteromers. As we show in figure 2A, the inhibitory effect of ghrelin on Ca_v currents was
 11 larger in neurons over-expressing GHSR than in neurons over-expressing D2R. Moreover,
 12 the effect of ghrelin in neurons co-expressing both GPCRs was not significantly different
 13 from neurons expressing GHSR alone. For quinpirole, we observed a larger effect in
 14 neurons over-expressing D2R alone compared to neurons expressing GHSR only (figure
 15 2B). Importantly, we found a significant reduction in the inhibitory effect of quinpirole in
 16 neurons co-expressing D2R and GHSR. This result indicates that D2R-GHSR co-expression
 17 modulates quinpirole-mediated inhibition of Ca_v currents, while ghrelin-mediated inhibition
 18 remains unaffected. We next plotted the percent inhibition by quinpirole and ghrelin for the
 19 sets of neurons in which we were able to evaluate the effect of both agonists, as we did
 20 previously for uninfected neurons (figure 1). Figure 2C displays a lack of correlation for each
 21 group and reveals that the data can be segregated into two groups: neurons over-expressing
 22 D2R (squares), which are highly sensitive to quinpirole and lowly sensitive to ghrelin; and
 23 neurons over-expressing either GHSR or both GPCRs (triangles and circles, respectively),
 24 which have similar sensitivity to quinpirole and ghrelin. These results support the idea that
 25 D2R-GHSR co-expression alters the agonist-induced D2R signaling pathway that inhibits

1 native Ca_v currents, while agonist-induced GHSR inhibition of Ca_v currents remains
 2 unaffected. This is in agreement with previous data from Kern *et al.* showing that the co-
 3 expression of D2R and GHSR modifies quinpirole signaling cascade in a hypothalamic
 4 neuronal cell line [12].



5
 6 **Figure 2. Simultaneous over-expression of D2R and GHSR in hypothalamic neurons**
 7 **reduces the inhibitory effect of quinpirole on barium currents.** **A.** Representative traces
 8 (top) of normalized barium current (I_{Ba}) from cultured mouse embryonic hypothalamic
 9 neurons transduced by lentivirus with D2R (+D2R, $n=10$), GHSR (+GHSR, $n=8$), or both
 10 receptors (+D2R +GHSR, $n=6$), before and after ghrelin application ($0.5 \mu M$, +Ghre). Bars
 11 (bottom) represent average percent inhibition of I_{Ba} by ghrelin. Statistical significance was
 12 evaluated by Kruskal-Wallis and Dunn's post-test. **B.** Representative traces (top) of I_{Ba} from
 13 cultured mouse embryonic hypothalamic neurons transduced by lentivirus with GHSR
 14 (+GHSR, $n=8$), D2R (+D2R, $n=13$), or both receptors (+D2R +GHSR, $n=6$) before and after
 15 quinpirole ($10 \mu M$, +Quin) application. Bars (bottom) represent average percent inhibition of
 16 I_{Ba} by quinpirole. Statistical significance was evaluated by Kruskal-Wallis and Dunn's post-
 17 test. **C.** Scatter plots of the percent inhibition of I_{Ba} by quinpirole versus ghrelin, calculated
 18 from hypothalamic neurons transduced by lentivirus with D2R (squares, $n=10$), GHSR
 19 (triangles, $n=8$), or both receptors (circles, $n=6$). Empty small symbols represent individual
 20 values. Correlation between the percentage of I_{Ba} inhibition by quinpirole and ghrelin was
 21 calculated in each data group and the Spearman's correlation coefficient, r , and P value
 22 were $r=-0.1945$ and $P=0.5755$ for +D2R, $r=-0.2143$ and $P=0.6191$ for +GHSR, and $r=0.2000$
 23 and 0.7139 for +D2R +GHSR not reaching statistical significance in any case. Colored big
 24 symbols represent the average values \pm SEM for ghrelin and quinpirole effects.

25 To gain insights of the mechanisms underlying the effects of D2R-GHSR co-expression on
 26 Ca_v currents, we ran experiments in HEK293T cells expressing the $Ca_v2.2$ channel. We
 27 chose this Ca_v subtype because it is the calcium channel most sensitive to GPCR activity
 28 and is the best studied in terms of its modulation by GHSR and D2R [5, 18-22]. We assayed
 29 the GHSR/D2R interaction in our experimental setting by FRET between GFP (donor) and
 30 mCherry (acceptor) by flow cytometry stimulating with a 488 nm laser. The experiments
 31 were done in HEK293T cells co-expressing GHSR-mCherry, soluble GFP and GHSR-

1 mCherry (negative control), GHSR-GFP and GHSR-mCherry (positive control see [23]) and
2 D2R-GFP and GHSR-mCherry. In supplementary figure S1A we showed that in the
3 condition co-expressing D2R-GFP and GHSR-mCherry the size of cell population with the
4 highest red fluorescent signal is significantly larger than the negative control condition and
5 not different from the positive control condition. Moreover we run an internalization assay to
6 evidence the interaction between GHSR and D2R in our system similar to the report by
7 Evans *et al.* [24] and others [25, 26]. In this case, we took advantage of the fact that GHSR
8 displays ghrelin-mediated internalization and explore if D2R co-internalize with GHSR. As
9 we show in the supplementary figure S1B we recapitulated the ghrelin mediated
10 internalization of GHSR by ghrelin as we have shown before [27]. More important, exposing
11 cells to 0.5 μM ghrelin reduces D2R in the cell surface and increases it in internal
12 compartments only when GHSR and D2R are co-expressed. Thus we confirmed that GHSR
13 and D2R interact in our experimental system *in vitro*. Next we performed patch clamp
14 experiments in cells co-transfected either D2R, GHSR, or both D2R and GHSR, with each
15 receptor at a 0.1 molar ratio to the $\text{Ca}_v2.2$ cDNA. We first tested the percentage of inhibition
16 of saturating doses of ghrelin (0.5 μM) [5, 28] on whole-cell calcium currents and found no
17 differences between cells expressing GHSR or both GPCRs (figure 3A). This observation
18 agrees with our previous data showing the effects of ghrelin on neurons over-expressing
19 GHSR as compared to neurons expressing both GPCRs. We next assayed the effect of 10
20 μM dopamine and found that the percentage of current inhibition is reduced by co-
21 expressing GHSR (figure 3B). In order to test whether constitutive GHSR activity is involved
22 in the reduction of the dopamine-mediated inhibition of $\text{Ca}_v2.2$ currents, we tested the effect
23 of 1 μM SPA (substance P analog), a GHSR ligand that stabilizes the receptor in an inactive
24 state [29] and also uncouples G_q from the receptor [30]. We pre-incubated cells co-
25 expressing D2R and GHSR for 20 hours with SPA and found that this maneuver restored
26 the inhibitory effect of dopamine to control levels (figure 3B). Moreover, we tested the effects
27 of dopamine in cells co-expressing D2R and a mutated version of GHSR (GHSRA204E), [5,
28 31]) that couples to G_q [30] but lacks constitutive activity. We found that the level of $\text{Ca}_v2.2$
29 current inhibition by dopamine was equal to that observed in D2R-expressing cells. These
30 results suggest that constitutive GHSR activity is necessary for the reduced effect of D2R
31 agonist on $\text{Ca}_v2.2$ currents in presence of GHSR. However we cannot rule out the possibility
32 that the rescue of the full inhibitory effect of dopamine by SPA and the GHSR mutant is due
33 to other causes: the inability of G_q to signal [30], and/or the lower degree of D2R-GHSR
34 heteromer formation. In this regard, Kern *et al.* (2012) have proposed that several GHSR
35 single mutants and SPA incubation modify the GHSR conformational state, preventing its
36 interaction with D2R [12].





Figure 3. $Ca_v2.2$ current inhibition by dopamine-mediated D2R activation is reduced in presence of GHSR in a GHSR constitutive activity-dependent manner. A. Representative traces (top) of normalized $Ca_v2.2$ calcium currents ($I_{Ca_v2.2}$) from HEK293T cells co-transfected with $Ca_v2.2$ and either GHSR (+GHSR, $n=7$), or GHSR and D2R (+D2R +GHSR, $n=13$), before and after ghrelin application ($0.5 \mu\text{M}$, +Ghre). Bars (bottom) represent average percent inhibition of $I_{Ca_v2.2}$. Statistical significance evaluated by unpaired t -test, $P=0.6049$. **B.** Representative traces (top) of normalized $I_{Ca_v2.2}$ from HEK293T cells co-transfected with $Ca_v2.2$ and either D2R (+D2R, $n=17$), or D2R and GHSR pre-incubated (+D2R +GHSR +SPA, $n=4$) or not (+D2R +GHSR, $n=11$) with SPA ($1 \mu\text{M}$), or D2R and GHSR A204E (+D2R +A204E, $n=8$), before and after dopamine application ($10 \mu\text{M}$, +Dopa). Statistical significance evaluated by Kruskal-Wallis and Dunn's post-test (versus +D2R).

In order to determine if the weaker effect of dopamine in presence of GHSR is due to a reduced affinity of dopamine to D2R and/or to a change in dopamine efficacy, we performed concentration-response curves for the dopamine effect on HEK293T transfected with $Ca_v2.2$ and either D2R alone or both D2R and GHSR. We found that the co-expression of GHSR significantly changes the maximum percent current inhibition (figure 4). The EC_{50} values were in the range of the K_D reported for dopamine binding to D2R [32]. The change in the efficacy of dopamine to inhibit $Ca_v2.2$ without a change in its affinity to bind the receptor suggests that either dopamine acts as a partial agonist when both receptors are expressed or the intracellular pathways available to D2R are changed in the presence of GHSR and consequently dopamine would behave as a biased agonist [33]. Interestingly, we found that the efficacy of dopamine to inhibit $Ca_v2.2$ currents was restored to control values when on HEK293T transfected with $Ca_v2.2$ and both D2R and GHSR were pre-incubated with SPA. Thus, this observation suggest that the conformational state of GHSR,

1 either per se or due to ability to activate signaling cascades, is important to impair dopamine-
 2 mediated inhibition of $Ca_v2.2$ currents via D2R.


3



4 **Figure 4. The efficacy of dopamine to inhibit $Ca_v2.2$ current is reduced when GHSR is**
 5 **co-expressed.** Dopamine concentration (0.01–1000 μM)–response curve of $Ca_v2.2$
 6 calcium current inhibition in HEK293T cells co-transfected with $Ca_v2.2$ and either D2R
 7 (squares), or D2R and GHSR (circles), pre-incubated or not with SPA (1 μM , +SPA).
 8 Symbols represent the average percent inhibition of calcium current and lines represent the
 9 fitted Hill equation. The *n* values for each condition are: 89 for +D2R, 48 for +D2R +GHSR
 10 and 28 for +D2R +GHSR +SPA (ranging from 3 to 25 for each data set). The maximum
 11 inhibition for the D2R and GHSR condition (99% confidence interval= 24.65 to 41.22) is
 12 significantly different from the one in the D2R (99% confidence interval= 44.30 to 53.16) and
 13 in the D2R and GHSR in presence of SPA (99% confidence Interval=42.26 to 72.88)
 14 conditions.

15 D2R couples to $G_{i/o}$, and the main reported downstream pathways activated by
 16 agonist are: 1) inhibition of adenylate cyclase by $G\alpha_{i/o}$, 2) direct activation of inward rectifier
 17 potassium channels (GIRK) [34], and 3) direct inhibition of native $Ca_v2.2$ calcium currents
 18 by $G\beta\gamma$ [17]. Dopamine-activated D2R also inhibits $Ca_v2.2$ through an additional $G\beta\gamma$ -
 19 independent mechanism observed in a heterologous system [20]. Moreover, D2R also
 20 activates PLC in a $G\beta\gamma$ -dependent manner [35]. Kern *et al.* (2012) have reported that the
 21 D2R and GHSR interaction perturbs the intracellular pathway downstream of $G_{i/o}$ activation
 22 by dopamine, increasing the activation of PLC and inducing the release of calcium from
 23 intracellular compartments [12]. This effect is mediated by G_q coupled to GHSR [23]. Thus,
 24 we hypothesized that G_q and $G\beta\gamma$ could be involved in the reduction of dopamine-mediated
 25 inhibition of $Ca_v2.2$ when D2R and GHSR are co-expressed. We therefore tested the effect
 26 of dopamine in cells co-expressing D2R and GHSR, with or without the addition of a G_q
 27 dominant negative protein (G_q DN) that occludes the downstream effect of G_q without
 28 altering GPCR conformation [36]. We found that the effect of dopamine on $Ca_v2.2$ currents
 29 remains unchanged in cells expressing only D2R and G_q DN. In contrast, we observed that

1 the degree of $Ca_v2.2$ inhibition by dopamine was restored to control value (expressing D2R)
 2 in cells co-expressing D2R, GHSR and G_q DN (figure 5A). Moreover, in order to address the
 3 specificity of GHSR effect on D2R signaling we used an irrelevant G_q protein coupled
 4 receptor. As we show in figure 5B replacing GHSR by the angiotensin II type 1 receptor
 5 (AT1R) failed to modify the dopamine mediated inhibition of $Ca_v2.2$ currents. Since it has
 6 been shown before that AT1R activation by angiotensin II inhibits Ca_v currents [37] here we
 7 also tested the functionality of AT1R and found that angiotensin II 1 μ M significantly reduces
 8 the $Ca_v2.2$ current in cells expressing AT1R and $Ca_v2.2$ ($31.53 \pm 6.94\%$, $n=3$ cells, $P=0.0451$,
 9 Student's t-test versus zero). In summary our results suggest that GHSR-mediated
 10 activation of G_q is required for the inhibitory effect of GHSR co-expression on the effects of
 11 dopamine-evoked D2R activity that target $Ca_v2.2$.



12
 13 **Figure 5. The reduced inhibition of $Ca_v2.2$ current by dopamine when GHSR is co-**
 14 **expressed depends on G_q protein. A. Representative traces (top) of normalized $Ca_v2.2$**
 15 **calcium current ($I_{Ca_v2.2}$) from HEK293T cells co-transfected with $Ca_v2.2$, D2R, and either**
 16 **pcDNA3.1(+), ($+D2R$, $n=6$), G_q DN ($+D2R +G_q$ DN, $n=11$), GHSR ($+D2R +GHSR$, $n=7$) or**
 17 **GHSR and G_q DN ($+D2R +GHSR +G_q$ DN, $n=11$), before and after dopamine application**
 18 **(10 μ M, +Dopa). Bars (bottom) represent the average percent inhibition of $I_{Ca_v2.2}$. Statistical**
 19 **significance was evaluated by Kruskal-Wallis and Dunn's post-test (versus +D2R). B.**
 20 **Representative traces (top) of normalized $Ca_v2.2$ calcium current ($I_{Ca_v2.2}$) from HEK293T**
 21 **cells co-transfected with $Ca_v2.2$ and D2R ($+D2R$, $n=4$), or with D2R and AT1R ($+D2R$**
 22 **+AT1R, $n=3$) before and after dopamine application (10 μ M, +Dopa). Bars (bottom)**
 23 **represent average percent inhibition of $I_{Ca_v2.2}$. Statistical significance evaluated by Student's**
 24 **t-test.**

Next we assayed the involvement of G $\beta\gamma$ subunits to the reduced effect of dopamine when D2R and GHSR are co-expressed. First, we tested the effect of dopamine on Ca $_v$ 2.2 currents in HEK293T cells co-expressing D2R and MAS-GRK2-ct, a G $\beta\gamma$ buffer peptide [38, 39], and found that buffering G $\beta\gamma$ reduced the effect of dopamine in D2R expressing cells [20]. Interestingly, the low level of dopamine-mediated Ca $_v$ 2.2 inhibition in cells co-expressing D2R and GHSR remained unchanged when MAS-GRK2-ct was also co-expressed (figure 6). Taken together, our results indicate that the G $\beta\gamma$ role in dopamine mediated inhibition of Ca $_v$ 2.2 is lost when GHSR is co-expressed. Previous studies have postulated that activation of one GPCR can transfer its G $\beta\gamma$ subunit to the G α subunit coupled to other GPCR, thereby reducing the availability of free G $\beta\gamma$ to exert downstream effects [40]. On the other hand Kern *et al.* [12] have shown that D2R and GHSR co-expression leads to a dopamine-induced PLC activation via G $\beta\gamma$. A putative explanation to conceal this report with our current data is to postulate that basally active GHSR takes G $\beta\gamma$ subunits from G $_{i/o}$ coupled to D2R to activate PLC. In this scenario is possible to think that the amount of G $\beta\gamma$ available to bind Ca $_v$ 2.2 would be reduced. This idea is in agreement with other reports demonstrating a close interaction between G $_{i/o}$ and G $_q$ when D2R and GHSR are co-expressed [23]. Thus, we hypothesize that constitutive GHSR activity could reduce the availability of free G $\beta\gamma$ to bind Ca $_v$ 2.2 and consequently impair dopamine-mediated D2R signaling pathways. In summary, the mechanisms involved in GHSR and D2R interaction seem to be very complex and may imply multiple pathways that differentially impact on other cellular structures different from Ca $_v$ 2.2.





Figure 6. The reduced inhibition of Ca $_v$ 2.2 current by dopamine when GHSR is co-expressed involves the loss of G $\beta\gamma$ -mediated inhibition of Ca $_v$ 2.2. Representative traces (top) of normalized $I_{Ca_v2.2}$ from HEK293T cells co-transfected with Ca $_v$ 2.2, D2R, and either pcDNA3.1(+) (+D2R, n=11), MAS-GRK2-ct (+D2R +MAS-GRK2-ct, n=13), GHSR (+D2R +GHSR, n=13) or GHSR and MAS-GRK2-ct (+D2R +GHSR +MAS-GRK2-ct, n=8)

1
2
3 1 *before and after dopamine application (10 μ M, +Dopa). Bars (bottom) represent the average*
4 2 *percent of $I_{CaV2.2}$ inhibition. Statistical significance was evaluated by Kruskal-Wallis and*
5 3 *Dunn's post-test (versus +D2R).*
6 4


7 4
8 5 In order to decipher how D2R and GHSR co-expression affects the dopamine- and
9 6 ghrelin-evoked inhibition of $Ca_v2.2$ we have normalized the size of currents and compared
10 7 the percent inhibition for each condition. However, we noticed that the basal $Ca_v2.2$ current
11 8 densities in pre-normalized data were consistently reduced in cells co-expressing both
12 9 receptors. Thus, we decided to investigate whether the co-expression of D2R and GHSR
13 10 affects basal $Ca_v2.2$ currents. First we run control experiments displayed in supplementary
14 11 figure S2 to confirm that manipulating the amount of cDNA for each GPCR plasmid
15 12 correlates with GPCR plasma membrane expression. We used GFP- and mOrange-tagged
16 13 versions of D2R and GHSR to determine fluorescent signal as a measurement of protein
17 14 expression. Once we confirmed this positive correlation we compared the basal current
18 15 levels of cells transfected with $Ca_v2.2$ alone (as a control) to cells transfected with D2R,
19 16 GHSR, or D2R plus GHSR, at the following two different GPCR: $Ca_v2.2$ molar ratios: 0.1, as
20 17 we used in all our previous experiments, and 0.5. We assayed 0.5 molar ratio because it is
21 18 the threshold for basal $Ca_v2.2$ current reduction by GHSR constitutive activity as we
22 19 described in our previous report [5]. We found a statistically significant reduction in basal
23 20 $Ca_v2.2$ current only in the conditions co-expressing D2R and GHSR (figure 7). In the case
24 21 of cells co-expressing D2R and GHSR in a 0.5 molar ratio, we found undetectable current
25 22 levels, indicating more severe effects on $Ca_v2.2$ currents at higher GPCR: $Ca_v2.2$ molar
26 23 ratio. Increasing the cDNA amount for D2R or GHSR alone did not produce statistically
27 24 significant changes in the current levels. However, in accordance with our aforementioned
28 25 study [5], we found that GHSR expression has a tendency to reduce basal $Ca_v2.2$ currents.
29 26 D2R expression did not show any clear tendency in changing $Ca_v2.2$ current levels, in
30 27 agreement with the non-conclusive data regarding D2R constitutive activity [41], though in
31 28 the 0.1 D2R: $Ca_v2.2$ molar ratio condition, we did observe a slight increase in $Ca_v2.2$ current
32 29 levels. This tendency of D2R expression to increase current levels at this molar ratio could
33 30 be related to a previous report showing that co-expression of D2R increases $Ca_v2.2$ surface
34 31 expression levels [20].
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1 **Figure 7. $Ca_v2.2$ basal current is reduced by GHSR and D2R co-expression.**
 2 Representative traces (top) of $Ca_v2.2$ calcium current ($I_{CaV2.2}$) from HEK293T cells co-
 3 transfected with $Ca_v2.2$ alone (Control, $n=86$), D2R, GHSR, or D2R plus GHSR in a 0.1
 4 (+D2R, $n=36$, +GHSR, $n=22$, +D2R +GHSR, $n=32$) or 0.5 GPCR: $Ca_v2.2$ molar ratio (+D2R,
 5 $n=41$, +GHSR, $n=14$, +D2R +GHSR, $n=53$). Bars (bottom) represent the average $Ca_v2.2$
 6 calcium current levels for each condition. Statistical significance was evaluated by Kruskal-
 7 Wallis and Dunn's post-test (versus Control, * $P<0.0001$).

8 Next we explored the possibility that the reduction in basal current density in presence
 9 of both GPCRs could be due to a tonic $G\beta\gamma$ mediated inhibition. We performed experiments
 10 using the same protocol described by Evans *et al.* [24] to assess the facilitation of current
 11 due to pre-pulse mediated release of $G\beta\gamma$ tonic binding to the $Ca_v2.2$. In control conditions
 12 (in absence of GPCRs) we found a reduction of amplitude of $Ca_v2.2$ calcium current after
 13 the pre-pulse (I_2). We consider this effect mediated by an incomplete recovery from current
 14 inactivation. In cells co-expressing GHSR and $Ca_v2.2$ we found I_2/I_1 values similar to control
 15 indicating lack of $G\beta\gamma$ tonic inhibition in this condition. On the other hand, when we applied
 16 this protocol to cells co-expressing $Ca_v2.2$ and D2R the I_2/I_1 is significantly larger than
 17 control. Moreover, the I_2/I_1 ratio obtained in cells co-expressing both GPCRs was similar to
 18 control conditions or in presence of only GHSR with $Ca_v2.2$. These data indicate that there
 19 is a tonic effect of D2R on $Ca_v2.2$ currents that can be release by a strong depolarizing pre-
 20 pulse (figure 8A). To confirm the involvement of $G\beta\gamma$ in the basal current facilitation we
 21 repeated the experiments co-expressing the MAS-GRK2-ct, the $G\beta\gamma$ buffer peptide. This
 22 maneuver occluded the pre-pulse mediated current facilitation by D2R co-expression (figure
 23 8B). This tonic inhibition of $Ca_v2.2$ currents by D2R co-expression may explain why we failed
 24 to observed the current density increase expected due to the reported D2R mediated rise of
 25 channel protein in the surface [5, 20]. More important, considering that $G\beta\gamma$ mediated
 26 inhibition of $Ca_v2.2$ by dopamine is lacking in presence of GHSR we could postulate that the

1 loss of tonic inhibition by D2R when co-expressing GHSR could be explained by G β γ
2 sequestration by basally active G $_q$ /GHSR complexes.




3 **Figure 8. D2R-mediated G β γ tonic inhibition of Ca $_v$ 2.2 is lost by GHSR co-expression.**

4 **A.** Representative traces (left) of Ca $_v$ 2.2 calcium current ($I_{CaV2.2}$) without (I_1) and with (I_2) a
5 pre-pulse at +150 mV from HEK293T cells co-transfected with Ca $_v$ 2.2 alone (Control, $n=14$),
6 D2R (+D2R, $n=12$), GHSR (+GHSR, $n=10$), or D2R plus GHSR (+D2R +GHSR, $n=11$) in a
7 0.1 GPCR:Ca $_v$ 2.2 molar ratio. Bars (right) represent the ratio between the peak current with
8 and without pre-pulse (I_2/I_1) for each condition. Statistical significance was evaluated by
9 ANOVA (versus Control). **B.** Representative traces (left) of Ca $_v$ 2.2 calcium current ($I_{CaV2.2}$)
10 without (I_1) and with (I_2) a pre-pulse at +150 mV from HEK293T cells co-transfected with
11 Ca $_v$ 2.2 alone (Control, $n=18$), D2R (+D2R, $n=11$), GHSR (+GHSR, $n=5$), or D2R plus GHSR
12 (+D2R +GHSR, $n=4$) and MAS-GRK2-ct in a 0.1 GPCR:Ca $_v$ 2.2 molar ratio. Bars (right)
13 represent the ratio between the peak current with and without pre-pulse (I_2/I_1) for each
14 condition. Statistical significance was evaluated by ANOVA (versus Control).

15 We next evaluated if the basal Ca $_v$ 2.2 current inhibition caused by D2R-GHSR co-
16 expression involves GHSR constitutive activity as we observed for the reduction in
17 dopamine evoked Ca $_v$ 2.2 currents. We measured basal Ca $_v$ 2.2 current levels in cells
18 expressing D2R or both receptors and evaluated the effect of either pre-incubating the cells
19 with the inverse agonist SPA or replacing GHSR with the mutant GHSRA204E [5, 22, 28,
20 31]. We found that under both of these conditions, the Ca $_v$ 2.2 current is restored to control
21 levels (that of D2R-expressing cells) (figure 9). These data indicate that GHSR constitutive
22 activity is indeed required for the reduction of basal Ca $_v$ 2.2 current by D2R-GHSR co-
23 expression. Next, we explored the intracellular pathways involved in the effect of D2R-GHSR
24 co-expression on basal Ca $_v$ 2.2 current and found that G $_q$ protein and the G β γ subunit are
25 required. Figure 10 displays the basal current reduction caused by D2R-GHSR co-
26 expression and the occlusion of this inhibitory effect by G $_q$ DN or MAS-GRK2-ct. Moreover,
27 we found that co-expression of AT1R, the G $_q$ PCR assayed in figure 5, also failed to modify

1 the basal $\text{Ca}_v2.2$ current when co-expressed with D2R ($I_{\text{Ca}_v2.2} + \text{D2R} = 22.21 \pm 5.49$ pA/pF, $n=11$ versus $I_{\text{Ca}_v2.2} + \text{D2R} + \text{AT1R} = 24.47 \pm 4.19$ pA/pF, $n=18$, $P=0.7444$, Student's t-test). Our
 2 previous study showed that GHSR constitutive activity inhibits $\text{Ca}_v2.2$ currents by a chronic
 3 mechanism that involves $G_{i/o}$ protein and channel density reduction at the plasma
 4 membrane, without requiring G_q and $G\beta\gamma$. Here we found that D2R-GHSR co-expression
 5 reduces basal $\text{Ca}_v2.2$ current at low GHSR expression levels by a novel signaling cascade.
 6 The basal inhibitory effect that we observed involves the same pathways that occlude the
 7 acute dopamine-mediated inhibition of $\text{Ca}_v2.2$ currents.

9 **Figure 9. Basal reduction of $\text{Ca}_v2.2$ calcium currents by GHSR and D2R co-expression**
 10 **requires GHSR constitutive activity. Representative traces (top) of $\text{Ca}_v2.2$ calcium**



11 *current ($I_{\text{Ca}_v2.2}$) from HEK293T cells co-transfected with $\text{Ca}_v2.2$ and D2R (+D2R, $n=51$), and*
 12 *either GHSR (+GHSR, $n=34$), GHSR and pre-incubated with SPA (+D2R +GHSR +SPA,*
 13 *$n=17$), or GHSRA204E (+D2R +A204E, $n=60$). Bars (bottom) represent the average $I_{\text{Ca}_v2.2}$*
 14 *levels for each condition. Statistical significance was evaluated by Kruskal-Wallis and*
 15 *Dunn's post-test (versus +D2R).*




Figure 10. Basal reduction of $Ca_v2.2$ calcium currents by GHSR and D2R co-expression requires G_q protein and $G\beta\gamma$ subunit. **A.** Representative traces (top) of $Ca_v2.2$ calcium current ($I_{CaV2.2}$) from HEK293T cells co-transfected with $Ca_v2.2$ and D2R (+D2R, n=48), and either GHSR (+D2R +GHSR, n=30), or GHSR and G_q DN (+D2R +GHSR + G_q DN, n=49). Bars (bottom) represent the average $I_{CaV2.2}$ levels for each condition. **B.** Representative traces (top) of $I_{CaV2.2}$ from HEK293T cells co-transfected with $Ca_v2.2$ and D2R (+D2R, n=32), and either GHSR (+D2R +GHSR, n=24) or GHSR and MAS-GRK2-ct (+D2R +GHSR +MAS-GRK2-ct, n=58). Bars (bottom) represent the average $I_{CaV2.2}$ values for each condition. Statistical significance was evaluated by Kruskal-Wallis and Dunn's post-test (versus +D2R).

In summary we found a novel mechanism for controlling $Ca_v2.2$ currents involving the co-expression of two physiologically relevant GPCRs. We propose that the G_q protein, mainly coupled to GHSR, captures $G\beta\gamma$ subunits from the $G_{i/o}$ protein coupled to D2R and consequently reduces the ability of $G\beta\gamma$ to binds $Ca_v2.2$ and may activates a new signaling cascade that basally inhibits $Ca_v2.2$. Thus, the GHSR-D2R interaction would modify the $G\beta\gamma$ -dependent effects of D2R and GHSR on $Ca_v2.2$. Moreover, the constitutive activation of GHSR via G_q and $G\beta\gamma$ subunits are required to reduce basal $Ca_v2.2$ currents when D2R is co-expressed. A similar interaction involving G_q and $G\beta\gamma$ has been described in studies that have also tested for D2R-GHSR heteromers [12, 23]. Both effects of D2R-GHSR co-expression on $Ca_v2.2$ currents require GHSR constitutive activity. This observation diverges from previous reports on the effects of the interaction between these GPCRs [12].

We demonstrated that co-expression of D2R and GHSR has an impact on calcium currents from native and recombinant $Ca_v2.2$. Our results suggest that the effect of dopamine on presynaptic calcium channels would be impaired by the presence of GHSR in

1
2
3 1 the presynaptic terminal. Since D2R are located at dopaminergic terminals [42], this effect
4 2 could lead to reduced negative feedback and thus to less regulation of dopamine release.
5 3 Moreover, since D2R and GHSR are also expressed in other neuronal types, such as
6 4 GABAergic [5, 43] and cholinergic neurons [18], this mechanism could also modify the effect
7 5 of dopamine on other neurotransmitter release. We also found that D2R-GHSR co-
8 6 expression in a heterologous system reduced basal $Ca_v2.2$ currents. If this mechanism
9 7 occurs in neurons, it is plausible that less $Ca_v2.2$ current would be available at presynaptic
10 8 terminals in neurons co-expressing D2R and GHSR. This mechanism could be important in
11 9 a physiological context such as the anorexigenic effect of dopamine observed in
12 10 hypothalamic neurons in mice, where the co-expression of D2R-GHSR is required for
13 11 calcium release from intracellular stores, leading to transcriptional activation [12]. The
14 12 differential modulation of $Ca_v2.2$ by dopamine in these neurons could contribute to this effect
15 13 by modifying the neuronal communication to appetite control by dopamine.

16 14 Our study leads to the question of how this novel control of $Ca_v2.2$ currents could be
17 15 regulated in neurons. One possibility is that regulation occurs by changing the amount of
18 16 D2R-GHSR heteromers formed in neurons. This could be modulated by changes in
19 17 expression levels of both receptors that have been widely described for both GHSR [44] and
20 18 D2R [45]. On the other hand, modifying GHSR constitutive activity also would impact the
21 19 mechanism that we described. In this context, the recently reported LEAP2 peptide [46]
22 20 gains importance since it has been proposed that it could act as a natural inverse agonist.

23 **Methods**

24 **Hypothalamic primary neuronal culture**

25 24 Wild type C57BL/6 mice were housed at IMBICE animal facility in a 12h light-dark
26 25 cycle and in a climate-controlled room. Mice were bred with *ad libitum* access to food and
27 26 water. Hypothalamic neurons were removed from mice at embryonic days 15-17 by orienting
28 27 brains on the dorsal face and removing the hypothalamus with forceps. Tissue was
29 28 processed as described in [22, 47]. These protocols were approved by the ethics committee
30 29 of IMBICE in accordance with the Guide for Care and Use of Laboratory Animals of the
31 30 National Research Council, USA.

32 **Human embryonic kidney (HEK) 293T cell culture**

33 33 HEK293T cells were used in all heterologous expression studies and for lentiviral
34 34 production. Cells were grown in Dulbecco's modified Eagle's medium (DMEM; Gibco) and
35 35 10% of fetal bovine serum was added (FBS; Internegocios). Every time cells achieved 80%
36 36 of confluence, they were harvested using citric saline 1X (0.135M KCl, 0.015M sodium
37 37 citrate) and plated in 22 mm diameter plates for electrophysiology assays and 100 mm
38 38 diameter dishes for lentiviral production.

39 **HEK293T cell transfection**

1 HEK293T cells were transfected for patch clamp experiments using Lipofectamine
2 2000 (Invitrogen) and Opti-MEM medium (Invitrogen) according to manufacturer protocols
3 with 2.5 μg of final cDNA. We used 0.2 μg of an eGFP-containing plasmid to identify
4 transfected cells. Plated cells were grown for 24 hours before transfection and 24 hours after
5 transfection to achieve appropriate expression levels.

6 HEK293T cells were transfected for lentiviral production with Polyethylenimine (PEI)
7 (cat 23966, Polysciences, Inc, USA) and Opti-MEM medium using 20 μg of cDNA / 40 μl of
8 PEI. Plated cells were grown for 24 hours before transfection and 48 hours after transfection
9 to allow for lentiviral production.

10 Plasmids containing the following were used for patch clamp experiments in
11 HEK293T cells: $\text{Ca}_v2.2$ (#AF055477), $\text{Ca}_v\beta_3$ (#M88751), $\text{Ca}_v\alpha_2\delta_1$ (#AF286488), (all Ca_v
12 subunits generously provided by Dr. Diane Lipscombe, Department of Neurosciences,
13 Brown University, Providence, USA), D2R (MG226860, Origene, donated by Dr. Marcelo
14 Rubinstein, INGEBI, Buenos Aires, Argentina), GHSR (GHSR, #AY429112, provided by Dr.
15 J. Marie, Université de Montpellier, Montpellier, France) and AT1R (Donated by Mark
16 Shapiro, University of Texas Health, San Antonio, USA). In indicated experiments we used
17 a 0.1 molar ratio of a point mutant of GHSR (GHSRA204E [5]), a G_q dominant-negative
18 mutant (G_q DN) (G_q -Q209L/D277N; Missouri S&T cDNA Resource Center, Rolla, MO, [36,
19 48]), or a C-terminal GPCR kinase 2 (MAS-GRK2-ct, gift from S.R. Ikeda, US National
20 Institutes of Health [38, 39]). Ca_v subunits were transfected together in every experiment,
21 each in a 1, 0.1, or 0.5 molar ratio of GPCR: $\text{Ca}_v2.2$. We fulfilled the amount of cDNA to 1
22 molar ratio with the empty plasmid pcDNA3.1(+) (Invitrogen), except in the condition using
23 both GPCRs at 0.5 GPCR: $\text{Ca}_v2.2$ molar ratio.

24 For third generation lentiviral system formation, we used a total of 20 μg of cDNA
25 divided as follows: 3.5 μg of the envelope plasmid pCMV-VSV-G, 4 μg of packaging plasmid
26 pMDLg/pRRE, 2.5 μg of packaging plasmids pRSV-Rev, and 10 μg of transfer vector
27 plasmid FU-GHSR-mOrange-W [5] or FU-D2R-GFP-W.

28 Transduction

29 Lentiviral particles were produced as described in [22]. Lentiviral particles containing
30 D2R or GHSR vector were generated and used to infect hypothalamic neurons on day 5 of
31 culture. To over-express both receptors, neurons were infected with both lentiviral particles.
32 Patch clamp experiments were performed nine days after infection.

33 Drugs

34 Ghrelin (Global Peptide, cat# PI-G-03) was used as a GHSR agonist. D2R-specific
35 agonists (-) Quinpirole hydrochloride (Q102, Sigma-Aldrich) and Dopamine hydrochloride
36 (H8502, Sigma-Aldrich) were used in neurons and HEK293T cells, respectively. [D-Arg1,D-
37 Phe5,D-Trp7,9,Leu11]-substance P analog (SPA, Santa Cruz Biotechnology, Inc.) was
38 used as a GHSR inverse agonist. Angiotensin II was used in HEK293T cells (A9525,
39 Sigma-Aldrich).

40 Electrophysiology

1
2
3 1 Transfected HEK293T cells were detached from plates using trypsin (0.25 mg/mL).
4 2 DMEM + 10% FBS was then added to inhibit trypsin activity, after which cells were rinsed
5 3 twice with DMEM. During patch clamp experiments cells were kept at room temperature (23
6 4 °C).

8 5 Whole-cell voltage clamp configuration mode was applied in all experiments.
9 6 Depolarizing pulses to 0 mV from a holding potential of -80 mV (for neurons) or to 10 mV
10 7 from -100 mV (for HEK293T cells) were used to evoke calcium currents for 30 ms every 10
11 8 seconds. For pre-pulse protocol we used the same as [24]. Pipette resistance range was
12 9 2-5 M Ω , and series resistances lower than 3 times the pipette resistance were admitted.

14 10 Currents were recorded using Axopatch 200 amplifier and PCLAMP8.2 (Molecular
15 11 Devices) or an EPC7 amplifier and PatchMaster (HEKA) sampled at 20 kHz and filtered at
16 12 10 kHz (-3dB). Cells with a leak current higher than 100 pA at -100 mV were discarded and
17 13 leak current was subtracted online using a P/-4 protocol. Perfusion was done by gravity
18 14 using 10 ml syringes containing bath solution placed 30 cm over the patch clamp chamber.
19 15 The flow rate was ~1 ml/min. Control, quinpirole, ghrelin, dopamine and angiotensin II
20 16 containing solutions were applied by different ports connected to the chamber. The liquid
21 17 junction potential between the internal and the external solution containing 2 mM CaCl₂ (see
22 18 below) was ~7.4 mV and between the internal and the external solution containing 10 mM
23 19 BaCl₂ solution (see below) was ~6.5 mV. These values were measured before experiments
24 20 and non-corrected thus all voltages showed were slightly more negative. All recordings were
25 21 obtained at room temperature (~24 °C).

28 22 Neurons were kept in high sodium maintenance solution until whole-cell
29 23 configuration was achieved and sodium currents were observed. Once sodium currents
30 24 were stabilized, the bath solution was changed to 10 mM barium- and TTX-containing
31 25 solution to record barium currents. Once barium currents reached a stable baseline, external
32 26 solution with ghrelin or quinpirole was applied in a random order. For recordings in neurons
33 27 ground electrode was placed in a separated compartment containing 2 M KCl connected
34 28 with the recording chamber containing bath solution by a 2 M KCl-agar salt bridge to avoid
35 29 change on junction potentials due to bath exchange during recordings.

39 31 - Internal pipette solution (in mM): 134 CsCl, 10 EGTA, 1 EDTA, 10 HEPES and 4
40 32 MgATP (pH 7.2 with CsOH).

42 33 - External calcium solution (2 mM) for HEK293T cells (in mM): 140 choline chloride,
43 34 10 HEPES, 1 MgCl₂·6H₂O and 2 CaCl₂·2H₂O (pH 7.3-7.4 with CsOH).

44 35 - External barium solution (10 mM) for neurons (in mM): 110 choline chloride, 10
45 36 HEPES, 10 glucose, 20 tetraethylammonium chloride, 1 MgCl₂·6H₂O, 10 BaCl₂·2H₂O and
46 37 0.001 tetrodotoxin (TTX; Sigma-Aldrich) (pH 7.3-7.4 with CsOH).

48 38 - High sodium maintenance solution (135 mM) for neurons (in mM): 10 HEPES, 1.2
49 39 MgCl₂·6H₂O, 2.5 CaCl₂·2H₂O, 4.7 KCl, 10 glucose and 135 NaCl (pH 7.3-7.4 with NaOH).

51 41 **Analysis and Statistics**

54 43 All currents were analyzed using pClampFit 10 software (Molecular Devices) at
55 44 minimum peak current during test pulse. In experiments studying agonist-evoked activity,

1 currents were normalized to the maximum value for each condition. In experiments studying
2 basal currents, currents were normalized based on the capacitance of each cell, which
3 represents the size of the cells. Representative traces of currents for each condition were
4 plotted using OriginPro 9 software.

5 Black dots on figures represent individual data points, and bars with error bars
6 display mean \pm SEM.

7 Statistical analysis was performed using GraphPad Prism 6 software. Kolmogorov–
8 Smirnov, Bartlett's and Brown-Forsythe's tests were used for population analysis. The
9 statistical tests used for each data set are specified in figure legends. Statistical significance
10 for all tests is 0.05. P-values above 0.05 were omitted. Concentration-response curves were
11 fitted using the Hill equation, and parameter comparison was achieved with GraphPad.

12 **Abbreviations**

13
14 Voltage-gated calcium channels (Ca_v), G protein-couple receptor (GPCR), dopamine
15 type 2 receptor (D2R), growth hormone secretagogue receptor (GHSR), Förster resonance
16 energy transfer (FRET), bioluminescence resonance energy transfer (BRET), adenylate
17 cyclase (AC), phospholipase C (PLC), complementary deoxyribonucleic acid (cDNA),
18 human embryonic kidney (HEK), [D-Arg1,D-Phe5,D-Trp7,9,Leu11]–substance P analog
19 (SPA), G protein-activated inward rectifier potassium channels (GIRK), G_q dominant
20 negative protein (G_q DN), C-terminal GPCR kinase 2 (MAS-GRK-ct), gamma-Aminobutyric
21 acid (GABA), liver-expressed antimicrobial peptide 2(LEAP2), Angiotensin II type 1 receptor
22 (AT1R).

23 **Author Information**

24 SCG, ERM, SSR and JR: Electrophysiology Laboratory of the Multidisciplinary
25 Institute of Cell Biology (IMBICE) [Argentine Research Council (CONICET), Scientific
26 Research Commission of the Providence of Buenos Aires (CIC-PBA) and National
27 University of La Plata (UNLP)], Calle 526 S/N entre 10 y 11, 1900 La Plata, Buenos Aires,
28 Argentina.

29 MP: Neurophysiology Laboratory of the Multidisciplinary Institute of Cell Biology
30 (IMBICE) [Argentine Research Council (CONICET), Scientific Research Commission of the
31 Providence of Buenos Aires (CIC-PBA) and National University of La Plata (UNLP)], Calle
32 526 S/N entre 10 y 11, 1900 La Plata, Buenos Aires, Argentina.

33 **Author Contributions**

34 SCG and ERM performed the experiments and data analysis. SSR cloned the FU-
35 D2R-GFP-W plasmid, produced the lentivirus and transduced neuronal cultures. SCG, ERM
36 and JR designed the experiments and wrote the manuscript. MP designed the internalization
37 assay and edit the final version of the manuscript. All authors reviewed the manuscript.

38 39 **Conflict of Interest**

1
2
3 1 The authors declare that they have no conflict of interest.
4

5 2 **Acknowledgment**

6
7 3 We thanks Cambria Chou-Freed for carefully reading and editing the manuscript.
8 4 This work was supported by the grant of the National Agency of Scientific and Technological
9 5 Promotion of Argentina (PICT 2015-3330, PICT 2017- 0602), National University of La Plata
10 6 (X765 and X860), and Argentine Research Council (Institutional grant PUE 2017).
11

12 7 **Supporting information**

13
14 8 The supporting information includes supplementary figure S1 confirming the
15 9 interaction between D2R and GHSR in our experimental system by flow cytometry and
16 10 internalization assays and supplementary figure S2 demonstrating that increasing GPCRs
17 11 cDNA amount in the transfection mix leads to higher protein expression levels in HEK293T
18 12 cells. These two figures are accompanied by a brief supplementary method section.
19

20 13 **References**

- 21
22 14 1. Gerber, K.J., K.E. Squires, and J.R. Hepler, *Roles for Regulator of G Protein Signaling Proteins*
23 15 *in Synaptic Signaling and Plasticity*. Mol Pharmacol, 2016. **89**(2): p. 273-86.
- 24 16 2. Leung, C.C.Y. and Y.H. Wong, *Role of G Protein-Coupled Receptors in the Regulation of*
25 17 *Structural Plasticity and Cognitive Function*. Molecules, 2017. **22**(7): p. 1239.
- 26 18 3. Ni, Q., S. Mehta, and J. Zhang, *Live-cell imaging of cell signaling using genetically encoded*
27 19 *fluorescent reporters*. FEBS J, 2018. **285**(2): p. 203-219.
- 28 20 4. Sato, J., N. Makita, and T. Iiri, *Inverse agonism: the classic concept of GPCRs revisited*
29 21 *[Review]*. Endocr J, 2016. **63**(6): p. 507-14.
- 30 22 5. Lopez Soto, E.J., F. Agosti, A. Cabral, E.R. Mustafa, V.M. Damonte, M.A. Gandini, S.
31 23 Rodriguez, D. Castrogiovanni, R. Felix, M. Perello, and J. Raingo, *Constitutive and ghrelin-*
32 24 *dependent GHSR1a activation impairs CaV2.1 and CaV2.2 currents in hypothalamic neurons*.
33 25 J Gen Physiol, 2015. **146**(3): p. 205-19.
- 34 26 6. Meye, F.J., G.M. Ramakers, and R.A. Adan, *The vital role of constitutive GPCR activity in the*
35 27 *mesolimbic dopamine system*. Transl Psychiatry, 2014. **4**: p. e361.
- 36 28 7. Sandhu, M., A.M. Touma, M. Dysthe, F. Sadler, S. Sivaramakrishnan, and N. Vaidehi,
37 29 *Conformational plasticity of the intracellular cavity of GPCR-G-protein complexes leads to G-*
38 30 *protein promiscuity and selectivity*. Proc Natl Acad Sci U S A, 2019. **116**(24): p. 11956-11965.
- 39 31 8. Okashah, N., Q. Wan, S. Ghosh, M. Sandhu, A. Inoue, N. Vaidehi, and N.A. Lambert, *Variable*
40 32 *G protein determinants of GPCR coupling selectivity*. Proc Natl Acad Sci U S A, 2019. **116**(24):
41 33 p. 12054-12059.
- 42 34 9. Hermans, E., *Biochemical and pharmacological control of the multiplicity of coupling at G-*
43 35 *protein-coupled receptors*. Pharmacol Ther, 2003. **99**(1): p. 25-44.
- 44 36 10. Borroto-Escuela, D.O., J. Carlsson, P. Ambrogini, M. Narvaez, K. Wydra, A.O. Tarakanov, X.
45 37 Li, C. Millon, L. Ferraro, R. Cuppini, S. Tanganelli, F. Liu, M. Filip, Z. Diaz-Cabiale, and K. Fuxe,
46 38 *Understanding the Role of GPCR Heteroreceptor Complexes in Modulating the Brain*
47 39 *Networks in Health and Disease*. Front Cell Neurosci, 2017. **11**: p. 37.
- 48 40 11. Farran, B., *An update on the physiological and therapeutic relevance of GPCR oligomers*.
49 41 Pharmacol Res, 2017. **117**: p. 303-327.
- 50 42 12. Kern, A., R. Albarran-Zeckler, H.E. Walsh, and R.G. Smith, *Apo-ghrelin receptor forms*
51 43 *heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of*
52 44 *DRD2 agonism*. Neuron, 2012. **73**(2): p. 317-32.

- 1
2
3 1 13. Van Craenenbroeck, K., *GPCR oligomerization: contribution to receptor biogenesis*. Subcell
4 2 Biochem, 2012. **63**: p. 43-65.
- 5 3 14. Fuxe, K., A. Tarakanov, W. Romero Fernandez, L. Ferraro, S. Tanganelli, M. Filip, L.F. Agnati,
6 4 P. Garriga, Z. Diaz-Cabiale, and D.O. Borroto-Escuela, *Diversity and Bias through Receptor-*
7 5 *Receptor Interactions in GPCR Heteroreceptor Complexes. Focus on Examples from*
8 6 *Dopamine D2 Receptor Heteromerization*. Front Endocrinol (Lausanne), 2014. **5**: p. 71.
- 9 7 15. Rediger, A., C.L. Piechowski, K. Habegger, A. Gruters, H. Krude, M.H. Tschop, G. Kleinau, and
10 8 H. Biebermann, *MC4R dimerization in the paraventricular nucleus and GHSR/MC3R*
11 9 *heterodimerization in the arcuate nucleus: is there relevance for body weight regulation?*
12 10 Neuroendocrinology, 2012. **95**(4): p. 277-88.
- 13 11 16. Beaulieu, J.M., S. Espinoza, and R.R. Gainetdinov, *Dopamine receptors - IUPHAR Review 13*.
14 12 Br J Pharmacol, 2015. **172**(1): p. 1-23.
- 15 13 17. Yan, Z., W.J. Song, and J. Surmeier, *D2 dopamine receptors reduce N-type Ca²⁺ currents in*
16 14 *rat neostriatal cholinergic interneurons through a membrane-delimited, protein-kinase-C-*
17 15 *insensitive pathway*. J Neurophysiol, 1997. **77**(2): p. 1003-15.
- 18 16 18. Momiyama, T. and E. Koga, *Dopamine D(2)-like receptors selectively block N-type Ca(2+)*
19 17 *channels to reduce GABA release onto rat striatal cholinergic interneurons*. J Physiol, 2001.
20 18 **533**(Pt 2): p. 479-92.
- 21 19 19. Momiyama, T., *Parallel decrease in omega-conotoxin-sensitive transmission and dopamine-*
22 20 *induced inhibition at the striatal synapse of developing rats*. J Physiol, 2003. **546**(Pt 2): p.
23 21 483-90.
- 24 22 20. Kisilevsky, A.E. and G.W. Zamponi, *D2 dopamine receptors interact directly with N-type*
25 23 *calcium channels and regulate channel surface expression levels*. Channels (Austin), 2008.
26 24 **2**(4): p. 269-77.
- 27 25 21. Mustafa, E.R., E.J. Lopez Soto, V. Martinez Damonte, S.S. Rodriguez, D. Lipscombe, and J.
28 26 Raingo, *Constitutive activity of the Ghrelin receptor reduces surface expression of voltage-*
29 27 *gated Ca(2+) channels in a CaVbeta-dependent manner*. J Cell Sci, 2017. **130**(22): p. 3907-
30 28 3917.
- 31 29 22. Martinez Damonte, V., S.S. Rodriguez, and J. Raingo, *Growth hormone secretagogue*
32 30 *receptor constitutive activity impairs voltage-gated calcium channel-dependent inhibitory*
33 31 *neurotransmission in hippocampal neurons*. J Physiol, 2018. **596**(22): p. 5415-5428.
- 34 32 23. Damian, M., V. Pons, P. Renault, C. M'Kadmi, B. Delort, L. Hartmann, A.I. Kaya, M. Louet, D.
35 33 Gagne, K. Ben Haj Salah, S. Denoyelle, G. Ferry, J.A. Boutin, R. Wagner, J.A. Fehrentz, J.
36 34 Martinez, J. Marie, N. Floquet, C. Gales, S. Mary, H.E. Hamm, and J.L. Baneres, *GHSR-D2R*
37 35 *heteromerization modulates dopamine signaling through an effect on G protein*
38 36 *conformation*. Proc Natl Acad Sci U S A, 2018. **115**(17): p. 4501-4506.
- 39 37 24. Evans, R.M., H. You, S. Hameed, C. Altier, A. Mezghrani, E. Bourinet, and G.W. Zamponi,
40 38 *Heterodimerization of ORL1 and opioid receptors and its consequences for N-type calcium*
41 39 *channel regulation*. J Biol Chem, 2010. **285**(2): p. 1032-40.
- 42 40 25. Schellekens, H., W.E. van Oeffelen, T.G. Dinan, and J.F. Cryan, *Promiscuous dimerization of*
43 41 *the growth hormone secretagogue receptor (GHS-R1a) attenuates ghrelin-mediated*
44 42 *signaling*. J Biol Chem, 2013. **288**(1): p. 181-91.
- 45 43 26. Wallace Fitzsimons, S.E., B. Chruscicka, C. Druelle, P. Stamou, K. Nally, T.G. Dinan, J.F. Cryan,
46 44 and H. Schellekens, *A ghrelin receptor and oxytocin receptor heterocomplex impairs oxytocin*
47 45 *mediated signalling*. Neuropharmacology, 2019. **152**: p. 90-101.
- 48 46 27. Barrile, F., C. M'Kadmi, P.N. De Francesco, A. Cabral, G. Garcia Romero, E.R. Mustafa, S.
49 47 Cantel, M. Damian, S. Mary, S. Denoyelle, J.L. Baneres, J. Marie, J. Raingo, J.A. Fehrentz, and

- 1
2
3 1 M. Perello, *Development of a novel fluorescent ligand of growth hormone secretagogue receptor based on the N-Terminal Leap2 region*. *Mol Cell Endocrinol*, 2019. **498**: p. 110573.
- 4 2
5 3 28. Pantel, J., M. Legendre, S. Cabrol, L. Hilal, Y. Hajaji, S. Morisset, S. Nivot, M.P. Vie-Luton, D.
6 4 Grouselle, M. de Kerdanet, A. Kadiri, J. Epelbaum, Y. Le Bouc, and S. Amselem, *Loss of*
7 5 *constitutive activity of the growth hormone secretagogue receptor in familial short stature*.
8 6 *J Clin Invest*, 2006. **116**(3): p. 760-8.
- 9 7 29. Mary, S., M. Damian, M. Louet, N. Floquet, J.A. Fehrentz, J. Marie, J. Martinez, and J.L.
10 8 Baneres, *Ligands and signaling proteins govern the conformational landscape explored by a*
11 9 *G protein-coupled receptor*. *Proc Natl Acad Sci U S A*, 2012. **109**(21): p. 8304-9.
- 12 10 30. Damian, M., S. Mary, M. Maingot, C. M'Kadmi, D. Gagne, J.P. Leyris, S. Denoyelle, G.
13 11 Gaibelet, L. Gavara, M. Garcia de Souza Costa, D. Perahia, E. Trinquet, B. Mouillac, S.
14 12 Galandrin, C. Gales, J.A. Fehrentz, N. Floquet, J. Martinez, J. Marie, and J.L. Baneres, *Ghrelin*
15 13 *receptor conformational dynamics regulate the transition from a preassembled to an active*
16 14 *receptor:Gq complex*. *Proc Natl Acad Sci U S A*, 2015. **112**(5): p. 1601-6.
- 17 15 31. Inoue, H., N. Kangawa, A. Kinouchi, Y. Sakamoto, C. Kimura, R. Horikawa, Y. Shigematsu, M.
18 16 Itakura, T. Ogata, K. Fujieda, and C. Japan Growth Genome, *Identification and functional*
19 17 *analysis of novel human growth hormone secretagogue receptor (GHSR) gene mutations in*
20 18 *Japanese subjects with short stature*. *J Clin Endocrinol Metab*, 2011. **96**(2): p. E373-8.
- 21 19 32. Gingrich, J.A. and M.G. Caron, *Recent advances in the molecular biology of dopamine*
22 20 *receptors*. *Annu Rev Neurosci*, 1993. **16**: p. 299-321.
- 23 21 33. Wacker, D., R.C. Stevens, and B.L. Roth, *How Ligands Illuminate GPCR Molecular*
24 22 *Pharmacology*. *Cell*, 2017. **170**(3): p. 414-427.
- 25 23 34. Kuzhikandathil, E.V., W. Yu, and G.S. Oxford, *Human dopamine D3 and D2L receptors couple*
26 24 *to inward rectifier potassium channels in mammalian cell lines*. *Mol Cell Neurosci*, 1998.
27 25 **12**(6): p. 390-402.
- 28 26 35. Hernandez-Lopez, S., T. Tkatch, E. Perez-Garci, E. Galarraga, J. Bargas, H. Hamm, and D.J.
29 27 Surmeier, *D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca²⁺*
30 28 *currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade*. *J*
31 29 *Neurosci*, 2000. **20**(24): p. 8987-95.
- 32 30 36. Lauckner, J.E., B. Hille, and K. Mackie, *The cannabinoid agonist WIN55,212-2 increases*
33 31 *intracellular calcium via CB1 receptor coupling to Gq/11 G proteins*. *Proc Natl Acad Sci U S*
34 32 *A*, 2005. **102**(52): p. 19144-9.
- 35 33 37. Yamada, E., T. Endoh, and T. Suzuki, *Angiotensin II-induced inhibition of calcium currents via*
36 34 *G(q/11)-protein involving protein kinase C in hamster submandibular ganglion neurons*.
37 35 *Neurosci Res*, 2002. **43**(2): p. 179-89.
- 38 36 38. Raingo, J., A.J. Castiglioni, and D. Lipscombe, *Alternative splicing controls G protein-*
39 37 *dependent inhibition of N-type calcium channels in nociceptors*. *Nat Neurosci*, 2007. **10**(3):
40 38 p. 285-92.
- 41 39 39. Kammermeier, P.J. and S.R. Ikeda, *Expression of RGS2 alters the coupling of metabotropic*
42 40 *glutamate receptor 1a to M-type K⁺ and N-type Ca²⁺ channels*. *Neuron*, 1999. **22**(4): p. 819-
43 41 29.
- 44 42 40. Ross, E.M., *Signal sorting and amplification through G protein-coupled receptors*. *Neuron*,
45 43 1989. **3**(2): p. 141-52.
- 46 44 41. Zhang, B., A. Albaker, B. Plouffe, C. Lefebvre, and M. Tiberi, *Constitutive activities and*
47 45 *inverse agonism in dopamine receptors*. *Adv Pharmacol*, 2014. **70**: p. 175-214.
- 48 46 42. Beaulieu, J.M. and R.R. Gainetdinov, *The physiology, signaling, and pharmacology of*
49 47 *dopamine receptors*. *Pharmacol Rev*, 2011. **63**(1): p. 182-217.

- 1
2
3 1 43. Wang, Q., C. Liu, A. Uchida, J.C. Chuang, A. Walker, T. Liu, S. Osborne-Lawrence, B.L. Mason,
4 2 C. Mosher, E.D. Berglund, J.K. Elmquist, and J.M. Zigman, *Arcuate AgRP neurons mediate*
5 3 *orexigenic and glucoregulatory actions of ghrelin*. *Mol Metab*, 2014. **3**(1): p. 64-72.
6 4 44. Fernandez, G., A. Cabral, M.F. Andreoli, A. Labarthe, C. M'Kadmi, J.G. Ramos, J. Marie, J.A.
7 5 Fehrentz, J. Epelbaum, V. Tolle, and M. Perello, *Evidence Supporting a Role for Constitutive*
8 6 *Ghrelin Receptor Signaling in Fasting-Induced Hyperphagia in Male Mice*. *Endocrinology*,
9 7 2018. **159**(2): p. 1021-1034.
10 8 45. Johnson, P.M. and P.J. Kenny, *Dopamine D2 receptors in addiction-like reward dysfunction*
11 9 *and compulsive eating in obese rats*. *Nat Neurosci*, 2010. **13**(5): p. 635-41.
12 10 46. M'Kadmi, C., A. Cabral, F. Barrile, J. Giribaldi, S. Cantel, M. Damian, S. Mary, S. Denoyelle, S.
13 11 Dutertre, S. Peraldi-Roux, J. Neasta, C. Oiry, J.L. Baneres, J. Marie, M. Perello, and J.A.
14 12 Fehrentz, *N-Terminal Liver-Expressed Antimicrobial Peptide 2 (LEAP2) Region Exhibits*
15 13 *Inverse Agonist Activity toward the Ghrelin Receptor*. *J Med Chem*, 2019. **62**(2): p. 965-973.
16 14 47. Agosti, F., S. Cordisco Gonzalez, V. Martinez Damonte, M.J. Tolosa, N. Di Siervi, H.B. Schioth,
17 15 C. Davio, M. Perello, and J. Raingo, *Melanocortin 4 receptor constitutive activity inhibits L-*
18 16 *type voltage-gated calcium channels in neurons*. *Neuroscience*, 2017. **346**: p. 102-112.
19 17 48. Yu, B. and M.I. Simon, *Interaction of the xanthine nucleotide binding G α mutant with*
20 18 *G protein-coupled receptors*. *J Biol Chem*, 1998. **273**(46): p. 30183-8.

21 19

22 20

23 21 For table of content use only

24 22 **Dopamine receptor type 2 (D2R) and ghrelin receptor (GHSR) co-expression alters**
25 23 **Ca_v2.2 modulation by G protein signaling cascades.**

26 24 Santiago Cordisco Gonzalez¹, Emilio R. Mustafá¹, Silvia S. Rodriguez¹, Mario Perello² and
27 25 Jesica Raingo^{1*}

28 26

